On the surface, biotechnology and value do not have much in common. Biotech companies lack predictable cash flows and calculable margins of safety; the sector is one of the market’s most volatile.

When I was in high school, I became fascinated with stock market investing. But after only a few weeks of studying it, one thing became clear: I had to pick a side. On one side were those captivated ...